Literature DB >> 26250579

Better allele-level matching improves transplant-related mortality after double cord blood transplantation.

Betül Oran1, Kai Cao2, Rima M Saliba3, Katayoun Rezvani3, Marcos de Lima4, Sairah Ahmed3, Chitra M Hosing3, Uday R Popat3, Yudith Carmazzi2, Partow Kebriaei3, Yago Nieto3, Gabriela Rondon3, Dana Willis2, Nina Shah3, Simrit Parmar3, Amanda Olson3, Brandt Moore2, David Marin3, Rohtesh Mehta3, Marcelo Fernández-Viña5, Richard E Champlin3, Elizabeth J Shpall3.   

Abstract

Cord blood transplant requires less stringent human leukocyte antigen matching than unrelated donors. In 133 patients with hematologic malignancies who engrafted after double cord blood transplantation with a dominant unit, we studied the effect of high resolution testing at 4 loci (-A, -B, -C, -DRB1) for its impact on 2-year transplant-related mortality. Ten percent of the dominant cord blood units were matched at 7-8/8 alleles using HLA-A, -B, -C, and -DRB1; 25% were matched at 6/8, 40% at 5/8, and 25% at 4/8 or less allele. High resolution typing at 4 loci showed that there was no 2-year transplant-related mortality in 7-8/8 matched patients. Patients with 5-6/8 matched dominant cord blood units had 2-year transplant-related mortality of 39% while patients with 4/8 or less matched units had 60%. Multivariate regression analyses confirmed the independent effect of high resolution typing on the outcome when adjusted for age, diagnosis, CD34(+) cell dose infused, graft manipulation and cord to cord matching. The worst prognostic group included patients aged over 32 years with 4/8 or less matched cord blood units compared with patients who were either younger than 32 years old independent of allele-level matching, or aged over 32 years but with 5-6/8 matched cord blood units (Hazard Ratio 2.2; 95% confidence interval: 1.3-3.7; P<0.001). Patients with 7-8/8 matched units remained the group with the best prognosis. Our data suggest that high resolution typing at 4 loci and selecting cord blood units matched at at least 5/8 alleles may reduce transplant-related mortality after double cord blood transplantation. Copyright© Ferrata Storti Foundation.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26250579      PMCID: PMC4591769          DOI: 10.3324/haematol.2015.127787

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  36 in total

1.  Allogeneic hematopoietic cell transplantation for hematologic malignancy: relative risks and benefits of double umbilical cord blood.

Authors:  Claudio G Brunstein; Jonathan A Gutman; Daniel J Weisdorf; Ann E Woolfrey; Todd E Defor; Theodore A Gooley; Michael R Verneris; Frederick R Appelbaum; John E Wagner; Colleen Delaney
Journal:  Blood       Date:  2010-08-04       Impact factor: 22.113

2.  Effect of conditioning regimen intensity on acute myeloid leukemia outcomes after umbilical cord blood transplantation.

Authors:  Betul Oran; John E Wagner; Todd E DeFor; Daniel J Weisdorf; Claudio G Brunstein
Journal:  Biol Blood Marrow Transplant       Date:  2011-01-11       Impact factor: 5.742

3.  An in vivo model of double-unit cord blood transplantation that correlates with clinical engraftment.

Authors:  Lamis K Eldjerou; Sonali Chaudhury; Ada Baisre-de Leon; Mai He; Maria E Arcila; Glenn Heller; Richard J O'Reilly; Juliet N Barker; Malcolm A Moore
Journal:  Blood       Date:  2010-06-29       Impact factor: 22.113

4.  Influence of infused cell dose and HLA match on engraftment after double-unit cord blood allografts.

Authors:  Sharon Avery; Weiji Shi; Marissa Lubin; Anne Marie Gonzales; Glenn Heller; Hugo Castro-Malaspina; Sergio Giralt; Nancy A Kernan; Andromachi Scaradavou; Juliet N Barker
Journal:  Blood       Date:  2010-12-13       Impact factor: 22.113

5.  Notch-mediated expansion of human cord blood progenitor cells capable of rapid myeloid reconstitution.

Authors:  Colleen Delaney; Shelly Heimfeld; Carolyn Brashem-Stein; Howard Voorhies; Ronald L Manger; Irwin D Bernstein
Journal:  Nat Med       Date:  2010-01-17       Impact factor: 53.440

6.  Cord blood units with low CD34+ cell viability have a low probability of engraftment after double unit transplantation.

Authors:  Andromachi Scaradavou; Katherine M Smith; Rebecca Hawke; Allison Schaible; Michelle Abboud; Nancy A Kernan; James W Young; Juliet N Barker
Journal:  Biol Blood Marrow Transplant       Date:  2009-11-22       Impact factor: 5.742

7.  Optimizing outcome after unrelated marrow transplantation by comprehensive matching of HLA class I and II alleles in the donor and recipient.

Authors:  E W Petersdorf; T A Gooley; C Anasetti; P J Martin; A G Smith; E M Mickelson; A E Woolfrey; J A Hansen
Journal:  Blood       Date:  1998-11-15       Impact factor: 22.113

8.  High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation.

Authors:  Stephanie J Lee; John Klein; Michael Haagenson; Lee Ann Baxter-Lowe; Dennis L Confer; Mary Eapen; Marcelo Fernandez-Vina; Neal Flomenberg; Mary Horowitz; Carolyn K Hurley; Harriet Noreen; Machteld Oudshoorn; Effie Petersdorf; Michelle Setterholm; Stephen Spellman; Daniel Weisdorf; Thomas M Williams; Claudio Anasetti
Journal:  Blood       Date:  2007-09-04       Impact factor: 22.113

9.  Single-unit dominance after double-unit umbilical cord blood transplantation coincides with a specific CD8+ T-cell response against the nonengrafted unit.

Authors:  Jonathan A Gutman; Cameron J Turtle; Thomas J Manley; Shelly Heimfeld; Irwin D Bernstein; Stanley R Riddell; Colleen Delaney
Journal:  Blood       Date:  2009-10-12       Impact factor: 22.113

10.  Factors predicting single-unit predominance after double umbilical cord blood transplantation.

Authors:  P Ramirez; J E Wagner; T E DeFor; B R Blazar; M R Verneris; J S Miller; D H McKenna; D J Weisdorf; P B McGlave; C G Brunstein
Journal:  Bone Marrow Transplant       Date:  2011-09-26       Impact factor: 5.483

View more
  12 in total

1.  Composite GRFS and CRFS Outcomes After Adult Alternative Donor HCT.

Authors:  Rohtesh S Mehta; Shernan G Holtan; Tao Wang; Michael T Hemmer; Stephen R Spellman; Mukta Arora; Daniel R Couriel; Amin M Alousi; Joseph Pidala; Hisham Abdel-Azim; Vaibhav Agrawal; Ibrahim Ahmed; A Samer Al-Homsi; Mahmoud Aljurf; Joseph H Antin; Medhat Askar; Jeffery J Auletta; Vijaya Raj Bhatt; Lynette Chee; Saurabh Chhabra; Andrew Daly; Zachariah DeFilipp; James Gajewski; Robert Peter Gale; Usama Gergis; Peiman Hematti; Gerhard C Hildebrandt; William J Hogan; Yoshihiro Inamoto; Rodrigo Martino; Navneet S Majhail; David I Marks; Taiga Nishihori; Richard F Olsson; Attaphol Pawarode; Miguel Angel Diaz; Tim Prestidge; Hemalatha G Rangarajan; Olle Ringden; Ayman Saad; Bipin N Savani; Hélène Schoemans; Sachiko Seo; Kirk R Schultz; Melhem Solh; Thomas Spitzer; Jan Storek; Takanori Teshima; Leo F Verdonck; Baldeep Wirk; Jean A Yared; Jean-Yves Cahn; Daniel J Weisdorf
Journal:  J Clin Oncol       Date:  2020-05-04       Impact factor: 44.544

2.  Optimizing selection of double cord blood units for transplantation of adult patients with malignant diseases.

Authors:  Giancarlo Fatobene; Fernanda Volt; Frederico Moreira; Lívia Mariano; Patrice Chevallier; Sabine Furst; Hélène Labussière-Wallet; Régis Peffault de la Tour; Eric Deconinck; Thomas Cluzeau; Nigel Russell; Dimitrios Karakasis; Edouard Forcade; Annalisa Ruggeri; Eliane Gluckman; Vanderson Rocha
Journal:  Blood Adv       Date:  2020-12-22

Review 3.  Optimal Practices in Unrelated Donor Cord Blood Transplantation for Hematologic Malignancies.

Authors:  Juliet N Barker; Joanne Kurtzberg; Karen Ballen; Michael Boo; Claudio Brunstein; Corey Cutler; Mitchell Horwitz; Filippo Milano; Amanda Olson; Stephen Spellman; John E Wagner; Colleen Delaney; Elizabeth Shpall
Journal:  Biol Blood Marrow Transplant       Date:  2017-03-06       Impact factor: 5.742

4.  High progression-free survival after intermediate intensity double unit cord blood transplantation in adults.

Authors:  Juliet N Barker; Sean M Devlin; Kristine A Naputo; Kelcey Skinner; Molly A Maloy; Lisa Flynn; Theodora Anagnostou; Scott T Avecilla; Andromachi Scaradavou; Christina Cho; Parastoo B Dahi; Sergio A Giralt; Boglarka Gyurkocza; Alan M Hanash; Katharine Hsu; Ann A Jakubowski; Esperanza B Papadopoulos; Jonathan U Peled; Miguel-Angel Perales; Craig S Sauter; Gunjan L Shah; Brian C Shaffer; Roni Tamari; James W Young; Mikhail Roshal; Richard J O'Reilly; Doris M Ponce; Ioannis Politikos
Journal:  Blood Adv       Date:  2020-12-08

Review 5.  Alternative Donor Graft Sources for Adults with Hematologic Malignancies: A Donor for All Patients in 2017!

Authors:  Tamila L Kindwall-Keller; Karen K Ballen
Journal:  Oncologist       Date:  2017-05-25

6.  The increase of the global donor inventory is of limited benefit to patients of non-Northwestern European descent.

Authors:  Suzanna M van Walraven; Anneke Brand; Jack N A Bakker; Martin B A Heemskerk; Suzan Nillesen; Marc B Bierings; Laura B Bungener; Bouke G Hepkema; Arjan Lankester; Arnold van der Meer; Kees Sintnicolaas; Judith A E Somers; Eric Spierings; Marcel G J Tilanus; Christien E M Voorter; Jan J Cornelissen; Machteld Oudshoorn
Journal:  Haematologica       Date:  2016-08-25       Impact factor: 9.941

7.  Class II HLA mismatch improves outcomes following haploidentical transplantation with posttransplant cyclophosphamide.

Authors:  Scott R Solomon; Michael T Aubrey; Xu Zhang; Katelin C Jackson; Lawrence E Morris; H Kent Holland; Melhem M Solh; Asad Bashey
Journal:  Blood Adv       Date:  2020-10-27

Review 8.  Milestones of Hematopoietic Stem Cell Transplantation - From First Human Studies to Current Developments.

Authors:  Mateja Kralj Juric; Sakhila Ghimire; Justyna Ogonek; Eva M Weissinger; Ernst Holler; Jon J van Rood; Machteld Oudshoorn; Anne Dickinson; Hildegard T Greinix
Journal:  Front Immunol       Date:  2016-11-09       Impact factor: 7.561

Review 9.  Haploidentical Transplantation in Children with Acute Leukemia: The Unresolved Issues.

Authors:  Sarita Rani Jaiswal; Suparno Chakrabarti
Journal:  Adv Hematol       Date:  2016-03-24

Review 10.  Is There Any Reason to Prefer Cord Blood Instead of Adult Donors for Hematopoietic Stem Cell Transplants?

Authors:  Meral Beksac
Journal:  Front Med (Lausanne)       Date:  2016-01-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.